Article Text

other Versions

PDF
Partial economic evaluation of clinical pharmacy interventions on the prescription of direct oral anticoagulants in a teaching hospital
  1. C Declaye1,
  2. A L Sennesael2,3,
  3. A S Larock1,3,
  4. A Spinewine1,2,3,
  5. B Krug4,5
  1. 1Department of Pharmacy, Université catholique de Louvain, CHU UCL Namur, Yvoir, Belgium
  2. 2Clinical Pharmacy Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium
  3. 3Namur Thrombosis and Hemostasis Center (NTHC), Universite de Namur, Namur, Belgium
  4. 4Quality and Safety Officer, Université catholique de Louvain, CHU UCL Namur, Yvoir, Belgium
  5. 5Institute of Health and Society, Université catholique de Louvain, Brussels, Belgium
  1. Correspondence to Professor B Krug, Quality and Safety Officer, Université catholique de Louvain, CHU UCL Namur, 1 Dr Therasse, Yvoir B-5530, Belgium; bruno.krug{at}uclouvain.be

Abstract

Background Potential inappropriate use of direct oral anticoagulants (DOACs) increases the risk of thromboembolic and haemorrhagic events.

Purpose To determine the net cost benefit of clinical pharmacy interventions on the prescription of DOACs.

Method We constructed a decision tree model using a public payer perspective. The appropriateness of the prescription was assessed using the Medication Appropriateness Index. The theoretical risks were collected from the literature and the individual potential risks were calculated using the Nesbit risk assignment conducted by two independent clinical pharmacists. Different costs were included based on diagnosis-related group coding and data in the literature. A univariate sensitivity analysis was performed.

Results Thirty-six of 75 patients had an inappropriate prescription of DOACs. The saved difference between avoided costs (7954€) and annualised medication costs and pharmacist cost (4323€) was 3631€ for 75 patients.

Conclusions In addition to the enhancement of the quality of the prescription, our results indicate that pharmacist interventions provide a positive net cost benefit.

  • partial economic evaluation
  • direct oral anticoagulants
  • risk assessment
  • clinical pharmacy interventions

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.